首页|曲克芦丁联合倍他司汀对急性脑梗死患者的应用效果

曲克芦丁联合倍他司汀对急性脑梗死患者的应用效果

扫码查看
目的 探究曲克芦丁联合倍他司汀对急性脑梗死(ACI)患者的应用效果.方法 选取安阳市第三人民医院神经内科2020年6月至2023年6月收治的100例ACI患者为研究对象,采用信封法将其分为对照组(n=50)和观察组(n=50).2组均给予常规治疗,对照组在常规治疗基础上给予倍他司汀口服,观察组在对照组基础上给予曲克芦丁静脉滴注.比较2组临床疗效、美国卒中量表(NIHSS)和简易精神状态量表(MMSE)评分、神经营养因子[胰岛素样生长因子-1(IGF-1)和脑源性神经营养因子(BDNF)]水平、血液流变学指标[血浆黏度(PSV)、纤维蛋白原(FIB)、全血黏度高切(HSV)、血小板黏附率(PAR)和全血黏度低切(LSV)]、炎性因子[白细胞介素(IL)-6、超敏C反应蛋白(hs-CRP)和肿瘤坏死因子-α(TNF-α)]水平以及不良反应发生情况.结果 观察组临床总有效率94.00%,显著高于对照组(78.00%,P<0.05);与对照组相比,观察组治疗后NIHSS更低,IGF-1、MMSE、BNDF更高(均 P<0.001);治疗后,2 组 IL-6、PAR、FIB、hs-CRP、PSV、HSV、TNF-α 及 LSV 水平均明显降低(P<0.05),且观察组低于对照组(P<0.05或P<0.001);2组不良反应发生率比较差异无统计学意义(P>0.05).结论 曲克芦丁联合倍他司汀治疗ACI患者安全有效,可抑制炎性因子水平,促进血流及神经功能恢复,有利于患者预后.
Clinical Effect of Troxerutin Combined with Betahistine on ACI Patients
Objective To analyze the clinical effect of troxerutin combined with betahistine on neurological function and hemorheology in patients with acute cerebral infarction(ACI).Methods A total of 100 patients with ACI admitted to our hospital from June 2020 to June 2023 were se-lected for the study,and were divided into the control group(50 cases)and the observation group(50 cases)using the random envelope method.Apart from conventional treatment for both groups,the control group was further given betahistine while the observation group was given troxerutin and betahistine.The clinical efficacy,the scores of the National Institute of Health Stroke Scale(NIHSS)and Mini-mental State examination(MMSE),the levels of neurotrophic fac-tors[insulin-like growth factor-1(IGF-1)and brain-derived neurotrophic factor(BDNF)],the blood rheology indexes[plasma viscosity(PSV),fibrinogen(FIB),whole blood viscosity high cut(HSV),platelet adhesion rate(PAR)and whole blood viscosity low cut(LSV)],levels of inflam-matory factors[interleukin(IL)-6,ultrasensitive C-reactive protein(hs-CRP)and tumor necrosis factor-alpha(TNF-alpha)],and the occurrence of adverse reactions were compared between the two groups.Results The clinical efficacy of the observation group was 94.00%,higher than 78.00%of the control group;the difference was statistically significant(P<0.05).Compared with the control group,the NIHSS of the observation group was lower after treatment,and the IGF-1,MMSE and BNDF were higher;the differences were statistically significant(P<0.05).After treatment,the levels of IL-6,PAR,FIB,hs-CRP,PSV,HSV,TNF-α and LSV in the two groups were significantly decreased,and those in the observation group were lower than those in the con-trol group(P<0.05).There was no significant difference in the incidence of adverse reactions be-tween the two groups(P>0.05).Conclusion Troxerutin combined with betahistine can be safe and effective in the management of ACI patients,which can inhibit the secretion of inflammatory mediators,promote the recovery of blood flow and nerve function,and is beneficial to the progno-sis of patients.

troxerutinbetahistineacute cerebral infarctionneurological functionhemorheology

韩雪、尚小洁、张利莎

展开 >

安阳市第三人民医院神经内科,河南安阳 455000

曲克芦丁 倍他司汀 急性脑梗死 神经功能 血液流变学

2024

实用临床医学
南昌大学

实用临床医学

影响因子:0.818
ISSN:1009-8194
年,卷(期):2024.25(2)
  • 15